Veracyte's Earnings Decline Arrives With Revenue Growth Still Intact

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Veracyte reports after market close, meaning Day 0 captures anticipatory trading before results are released, while Day +1 reflects the market's first full session to react to actual earnings.

VCYT has exhibited dramatic post-earnings volatility, with an average absolute Day +1 move of 14.82% following the eight most recent reports. The stock has moved higher on Day +1 in six of the past eight earnings releases, with particularly explosive reactions in recent quarters: +24.93% in May 2026, +27.46% in November 2025, and +23.97% in August 2024. Even the two negative reactions were substantial, including a -14.99% decline in February 2025.

Day 0 moves have been more muted at 1.71% on average, consistent with after-hours reporting where anticipatory positioning is limited. However, the Day +1 range of 15.34% underscores the significant intraday volatility investors should expect, with the stock frequently trading across double-digit percentage ranges as the market digests results and management commentary. Given the current setup—where estimates have been revised downward and the year-over-year comparison has turned negative—investors should prepare for potentially heightened volatility if results deviate meaningfully from the $0.29 consensus.

Part 2.2: Options Market Expected Move

The options market is pricing a 9.00% expected move (±$5.02, range $50.70-$60.73) for the August monthly expiration, which is notably lower than VCYT's average historical Day +1 move of 14.82%. This suggests options traders may be underpricing potential volatility, particularly given the stock's recent pattern of explosive post-earnings reactions exceeding 20% in three of the past four quarters.

Part 3: What Analysts Are Saying

Analysts maintain a bullish stance on Veracyte with an average recommendation of 4.31 out of 5.00, reflecting strong buy sentiment. The consensus includes 9 Strong Buy ratings, 1 Moderate Buy, 2 Hold ratings, and just 1 Strong Sell, demonstrating broad confidence in the company's prospects despite near-term estimate pressure.

The average price target of $58.58 implies modest upside of approximately 5.2% from the current price of $55.71, with a wide range spanning from a low of $45.00 to a high of $70.00. This 25-point spread reflects differing views on the company's growth trajectory and valuation, though the high-end target suggests some analysts see potential for 25%+ appreciation.

Sentiment has improved over the past month, with Strong Buy ratings increasing from 8 to 9, pushing the average recommendation higher from 4.25 to 4.31. This upgrade activity—occurring even as earnings estimates have been revised downward—suggests analysts are looking past near-term compression and focusing on the company's longer-term positioning in the molecular diagnostics market. The strengthening conviction among the analyst community provides a supportive backdrop heading into tomorrow's report, though the relatively modest price target upside indicates expectations are already well-reflected in the current valuation.

Part 4: Technical Picture

Veracyte's technical setup heading into earnings shows a stock in consolidation after a strong longer-term advance. The Barchart Technical Opinion currently registers an 80% Buy signal, down slightly from 88% Buy both one week and one month ago, indicating some recent loss of momentum while maintaining an overall bullish posture.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal suggests near-term momentum has cooled, reflecting recent price weakness
• Medium-term (100% Buy): Strong buy signal indicates the intermediate trend remains firmly positive despite short-term consolidation
• Long-term (100% Buy): Strong buy signal confirms the broader uptrend is intact, supported by the stock's position well above longer-term moving averages

Trend Characteristics: The combination of Strong strength and Average direction suggests VCYT is in a powerful uptrend that has entered a period of consolidation or digestion, typical behavior ahead of a potentially market-moving catalyst like earnings.

The stock is trading at $55.71, positioned below its 5-day ($56.29), 10-day ($57.46), and 20-day ($57.58) moving averages, confirming recent near-term weakness. However, the price remains well above its 50-day ($52.86), 100-day ($43.36), and 200-day ($41.70) moving averages, illustrating that the longer-term uptrend remains firmly intact despite the recent pullback.

The technical picture presents a stock that has pulled back from recent highs but maintains strong support from rising longer-term moving averages. The 50-day average at $52.86 represents the first significant support level, approximately 5% below current prices. The recent consolidation below short-term moving averages may actually provide a more favorable risk/reward setup for earnings, as the stock isn't extended heading into the report. However, a disappointment could quickly test the 50-day support, while a beat consistent with the company's recent pattern could propel VCYT back above the $57-58 resistance zone defined by the 10- and 20-day averages. The strong medium and long-term buy signals suggest any earnings-driven weakness would likely find buyers, while a positive surprise has room to run given the stock isn't overbought on shorter timeframes.